Q-omics provides the consensus-scored ABITRAM profile across patient tissues and cancer cell-line models. ABITRAM expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ABITRAM is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, ABITRAM RNA expression shows 19,445 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRP, and COAD as cancer lineages where ABITRAM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABITRAM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABITRAM survival associations across molecular data types. ABITRAM RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABITRAM RNA expression–survival associations across cancer types. High ABITRAM expression shows unfavorable associations in KIRP, ACC, LIHC, HNSC and LGG, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ABITRAM RNA expression.
This table summarizes ABITRAM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ABITRAM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABITRAM shows lower tumor expression in THCA and KICH and higher tumor expression in COAD, HNSC, LIHC and BLCA. The COAD box plot shows higher ABITRAM RNA expression in tumor versus normal tissue (log2 FC = +0.657, t-test p < 0.001).
This table shows molecular features associated with ABITRAM in patient tissues and cancer cell lines. In patient samples, ABITRAM shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ABITRAM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
